IRCCS, Istituto delle Scienze Neurologiche di Bologna (Reference Center for Rare and Complex Epilepsies-EpiCARE), Bologna, Italy.
Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Clin Genet. 2020 Nov;98(5):477-485. doi: 10.1111/cge.13823. Epub 2020 Sep 1.
Developmental and epileptic encephalopathies (DEE) encompass rare, sporadic neurodevelopmental disorders and usually with pediatric onset. As these conditions are characterized by marked clinical and genetic heterogeneity, whole-exome sequencing (WES) represents the strategy of choice for the molecular diagnosis. While its usefulness is well established in pediatric DEE cohorts, our study is aimed at assessing the WES feasibility in adult DEE patients who experienced a diagnostic odyssey prior to the advent of this technique. We analyzed exomes from 71 unrelated adult DEE patients, consecutively recruited from an Italian cohort for the EPI25 Project. All patients underwent accurate clinical and electrophysiological characterization. An overwhelming percentage (90.1%) had already undergone negative genetic testing. Variants were classified according to the American College of Medical Genetics and Genomics guidelines. WES disclosed 24 (likely) pathogenic variants among 18 patients in epilepsy-related genes with either autosomal dominant, recessive or X-linked inheritance. Ten of these were novel. We obtained a diagnostic yield of 25.3%, higher among patients with brain malformations, early-onset epilepsy and dysmorphisms. Despite a median diagnostic delay of 38.7 years, WES analysis provided the long-awaited diagnosis for 18 adult patients, which also had an impact on the clinical management of 50% of them.
发育性和癫痫性脑病 (DEE) 包括罕见的、散发性神经发育障碍,通常在儿童时期发病。由于这些疾病的临床和遗传异质性明显,外显子组测序 (WES) 是分子诊断的首选策略。虽然它在儿科 DEE 队列中的有效性已得到充分证实,但我们的研究旨在评估 WES 在经历过这种技术之前的诊断探索期的成年 DEE 患者中的可行性。我们分析了来自意大利 EPI25 项目的一个意大利队列中连续招募的 71 名无关成年 DEE 患者的外显子组。所有患者均接受了准确的临床和电生理特征分析。绝大多数(90.1%)患者已经进行了阴性基因检测。变异根据美国医学遗传学和基因组学学院的指南进行分类。WES 在与常染色体显性、隐性或 X 连锁遗传相关的基因中发现了 18 名癫痫患者中的 24 个(可能)致病性变异。其中 10 个是新发现的。我们在脑畸形、早发性癫痫和发育异常的患者中获得了 25.3%的诊断率。尽管中位诊断延迟为 38.7 年,但 WES 分析为 18 名成年患者提供了期待已久的诊断,其中 50%的患者的临床管理也因此受到影响。